A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: Analysis of data from the literature

Lung Cancer

Volumn 84, Issue 1, 2014, Pages 7-12

  Kong, Cheng ^a   Guo, Wen jie ^a   Zha, Wen wu ^a   Zhu, Xiang zhi ^a   Huang, Sheng fu ^a   Zhang, Ye wei ^a   Xu, Jian hua ^a   He, Xia ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biological equivalent dose; Non small cell lung cancer; Stereotactic body radiotherapy; The linear quadratic model

Indexed keywords

BIOLOGICAL EQUIVALENT DOSE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE SEVERITY; DOSIMETRY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

BIOLOGICAL EQUIVALENT DOSE; NON-SMALL CELL LUNG CANCER; STEREOTACTIC BODY RADIOTHERAPY; THE LINEAR QUADRATIC MODEL;

CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 84896732926     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.015     Document Type: Review

References (48)

1. Wulf J., Haedinger U., Oppitz U., et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004, 60:186-196.
2. Xia T.Y., Li H.Q., Sun Q.X., et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:117-125.
3. Baumann P., Nyman J., Lax I., et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006, 45:787-795.
4. Hof H., Herfarth K., Unter M., et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003, 56:335-341.
5. Lee S.W., Choi E.K., Park H.J., et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003, 40:309-315.
6. Fakiris A., McGarry R., Yiannoutsos C., et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009, 75:677-682.
7. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. J Am Med Assoc 2010, 303:1070-1076.
8. Le Q.T., Loo B.W., Ho A., et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for Lung tumors. J Thorac Oncol 2006, 1:802-809.
9. Koto M., Takai Y., Ogawa Y. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007, 85:429-434.
10. Bonfili P., Staso M.D., Gravina G.L., et al. Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer. Lung Cancer 2010, 67:81-85.
11. Ng A.W.Y., Tung S.Y., Wong V.Y.W. Hypofractionated stereotacticradiotherapy for medically inoperable stage I non-small cell lung cancer-report on clinical outcome and dose to critical organs. Radiother Oncol 2008, 87:24-28.
12. Hoyer M., Roed H., Hansen A.T., et al. Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:S128-S135. Supplement.
13. Nyman J., Johansson K.A., Hult́en U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--Mature results for medically inoperable patients. Lung Cancer 2006, 51:97-103.
14. Baumann P., Nyman J., Hoyer M., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
15. Ricardi U., Filippi A.R., Guarneri A., et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 2010, 68:72-77.
16. Hamamoto Y., Kataoka M., Yamashita M., et al. Local control of metastatic lung tumors treated with SBRT of 48Gy in four fractions: in comparison with primary lung cancer. Jpn J Clin Oncol 2010, 40:125-129.
17. Faria S.L., Souhami L., Portelance L., et al. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable early stage non-small cell lung cancer. Radiat Oncol 2006, 1:42.
18. Hara R., Itami J., Kondo T. Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol 2002, 63:159-163.
19. Kim H., Ahn Y.C., Park H.C., et al. Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer. J Thorac Oncol 2010, 5:526-532.
20. Timmerman R.D., Story M. Stereotactic body radiation therapy: a treatment in need of basic biological research. Cancer J 2006, 12:19-20.
21. Brown J.M., Koong A.C. High-dose single-fraction radiotherapy: exploiting a new biology?. Int J Radiat Oncol Biol Phys 2008, 71:324-325.
22. Kocheret M., et al. Computer simulation of cytotoxic and vascular effects of radiosurgery in solid and necrotic brain metastases. Radiother Oncol 2000, 54:149-156.
23. Karlssonet B., et al. Long-term results after fractionated radiation therapy for large brain arteriovenous malformations. Neurosurgery 2005, 57:42-49.
24. Wulf J., Baier K., Mueller G., et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005, 77:83-87.
25. Geh J., Bond S., Bentzen S.M. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006, 78:236-244.
26. Bentzen S.M. Dose-response relationship in radiotherapy. Basic clinical radiobiology 1997, 78-86. Arnold, London. 2nd ed. G.G. Steel (Ed.).
27. Marks L.B., et al. Extrapolating hypofractionated radiation schemes from radiosurgery data: regarding Hallet al. IJROBP 1991;21:819-24; and Hall and Brenner, IJROBP 1993;25:381-85. Int J Radiat Oncol Biol Phys 1995, 32:274-276.
28. Guerrero M., Li X.A. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 2004, 49:4825-4835.
29. Wang J.Z., Mayr N.A., et al. A generalized linear-quadratic formula for high-dose-rate brachytherapy and radiosurgery. Int J Radiat Oncol Biol Phys 2007, 69:S619-S620.
30. Park C., Papiez S., Zhang M., et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:847-852.
31. Astrahan M. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. Med Phys 2008, 35:4161-4172.
32. Joiner M.C. Quantifying cell kill and cell survival. Basic clinical radiobiology 2009, 41-55. Hodder Arnold, London. 4th ed. M.C. Joiner, A.J. van der Kogel (Eds.).
33. Glatstein E. The omega on alpha and beta. Int J Radiat Oncol Biol Phys 2011, 81:319-320.
34. Chapman J.D., Gillespie C.J. The power of radiation biophysics-let's use it. Int J Radiat Oncol Biol Phys 2012, 84:309-311.
35. Brenner D.J., Rainer K.S., Peters L.J., et al. We forget at our peril the lessons built into the a/b model. Int J Radiat Oncol Biol Phys 2012, 82:1312-1314.
36. Kirkpatrick J.P., Meyer J.J., Marks L.B. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 2008, 18:240-243.
37. Brenner D.J. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008, 18:234-239.
38. Kirkpatrick J.P., Brenner D.J., Orton C.G. The linear-quadratic model is inappropriate to model highdoseper fraction effects in radiosurgery. Med Phys 2009, 36:3381-3384.
39. Krämer M., Weyrather W.K., Scholz M. The increased biological effectiveness of heavy charged particles: from radiobiology to treatment planning. Technol Cancer Res Treat 2003, 2:427-436.
40. Curtis S.B. Lethal and potentially lethal lesions induced by radiation-a unified repair model. Radiat Res 1986, 106:252-270.
41. McKenna F.W., Ahmad S. Fitting techniques of cell survival curves in high-dose region for use in stereotactic body radiation therapy. Phys Med Biol 2009, 54:1593-1608.
42. Carlone M., Wilkins D., Raaphorst P. The modified linear-quadratic model of Guerrero and Li can be derived from a mechanistic basis and exhibits linear-quadratic-linear behaviour. Phys Med Biol 2005, 50:L9-L13.
43. Kavanagh B.D., Newman F. Toward a unified survival curve: in regard to Park et al. and Krueger et al. (Int J Radiat Oncol Biol Phys 2008;70:847-852) and Kruegeret al. (Int J Radiat Oncol Biol Phys 2007;69:1262-1271). Int J Radiat Oncol Biol Phys 2008, 71:958-959.
44. Astrahan M. BED calculations for fractions of very highdose: in regard to Parket al. (Int J Radiat Oncol Biol Phys 2007;69:S623-S624). Int J Radiat Oncol Biol Phys 2008, 71:963.
45. Fowler J.F. Linear quadratics is alive and well: In regard to Parket al. (Int J Radiat Oncol Biol Phys 2008;70:847-852). Int J Radiat Oncol Biol Phys 2008, 72:957.
46. McKenna F., Ahmad S. Toward a unified survival curve: in regard to Kavanagh and Newman (Int J Radiat Oncol Biol Phys 2008;71:958-959) and Parket al. (Int J Radiat Oncol Biol Phys 2008;70:847-852). Int J Radiat Oncol Biol Phys 2009, 73:640.
47. Onishi H., Araki T., Shirato H., et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 101:1623-1631.
48. Partridgea M., Ramos M., Sardaro A., et al. Dose escalation for non-small cell lung cancer: analysis and modeling of published literature. Radiother Oncol 2011, 99:6-11.